Background
The early Xenopus embryonic cell cycle is driven by fluctuations in the level of cyclin B, the activating subunit of the protein kinase p34 cdc2 [1, 2] . While cyclin B is continuously synthesized, its level is controlled by the periodic activation of a highly substrate-specific proteolytic system: cyclin B is stable during interphase, but is rapidly degraded late in mitosis as cells undergo anaphase. Overexpression of nondegradable mutants of cyclin B arrests cells in telophase with sustained p34 cdc2 kinase activity [3] [4] [5] [6] [7] [8] , indicating that cyclin proteolysis is necessary for kinase inactivation and subsequent exit from mitosis. It is therefore the regulated activation and inactivation of cyclin proteolysis that drives the early embryonic cell cycle [9] . Cyclin B is degraded by the ubiquitin-proteasome pathway [10, 11] , in which the covalent attachment of ubiquitin to cyclin B targets the protein for degradation by the 26S proteasome [12, 13] . The ubiquitination of cyclin B requires the presence of a specific degradation signal in cyclin called the destruction box (D box) [10] . Several components required for cyclin ubiquitination have been identified recently by biochemical and genetic approaches ( [14] [15] [16] [17] [18] ; reviewed in [19] [20] [21] [22] ). In addition to the ubiquitin-activating enzyme E1, cyclin ubiquitination involves at least two distinct E2 enzymes, or ubiquitin-conjugating enzymes, neither of which is cell-cycle regulated [14, 16] . The mitotic specificity of cyclin ubiquitination occurs through activation of a cyclin-ubiquitin ligase or E3 activity that is associated with a large protein complex, called the cyclosome in clams [17] or the anaphase-promoting complex (APC) in vertebrates and yeast [16] . APC purified from Xenopus contains at least eight distinct proteins [16] , including homologs of budding yeast CDC16 and CDC27, which are essential for the onset of anaphase in both fungi and mammalian cells [15, 18] .
Previous studies have identified several E2 activities that can cooperate with the cell-cycle regulated E3 component to ubiquitinate cyclin B. In clams, a single E2 activity called E2-C can complement partially purified cyclosome preparations to ubiquitinate cyclin B [14, 17] . In Xenopus, two distinct E2 activities can cooperate with APC to ubiquitinate cyclin B in a D box-dependent manner. One of these has been identified as a homolog of budding yeast UBC4 [16] . This E2 also participates in the degradation of several other classes of proteins, including the MAT␣2 repressor [23] , the tumor suppressor p53 [24, 25] , and misfolded or damaged proteins [26] . The second E2 activity in Xenopus, called UBCx, has not been molecularly characterized [16] . The chromatographic characteristics of UBCx indicate that this protein is not a Xenopus homolog of UBC9, a protein implicated in cyclin proteolysis in yeast [27] . It remains possible, however, that UBCx is the Xenopus homolog of clam E2-C.
To identify UBCx, and to understand the mechanism by which UBC4 and UBCx cooperate with APC to ubiquitinate cyclin B, we have purified and cloned UBCx from Xenopus. UBCx is a novel ubiquitin-conjugating enzyme, most closely related to yeast and human UBC2. Recombinant UBCx can function with purified APC to ubiquitinate cyclin B in a D box-dependent manner. Dose-response experiments indicate that UBC4 and UBCx are active over a similar range of concentrations. At saturating enzyme concentrations, UBCx converts a greater proportion of substrate into ubiquitin conjugates. However, the conjugates generated by UBCx are of lower molecular mass than those generated with UBC4. These data suggest that although UBCx and UBC4 function through a similar APC-dependent mechanism, the pattern of conjugates produced is influenced by the nature of the E2, indicating that these E2s may play distinct roles in cyclin degradation.
Results

Purification and molecular cloning of UBCx
We have shown previously that components of the mitotic cyclin ubiquitination machinery in Xenopus egg extracts can be separated into cell-cycle regulated and unregulated fractions by Resource Q chromatography [16] . The Qbinding fraction, Q2, contains the ubiquitin-activating enzyme (E1) and the mitotically-regulated 20S complex (APC) that possesses a cyclin-specific ubiquitin ligase (E3) activity. The Q flowthrough fraction, Q1, contains two distinct E2s that each supports cyclin ubiquitination in conjunction with fraction Q2. One of the two UBCs was previously shown to be a homolog of yeast UBC4 [16] . To complete our identification of the components involved in cyclin ubiquitination, we set out to purify the other E2 enzyme, UBCx.
Because the activity of UBCx is not cell cycle-regulated, we used interphase extracts as our starting material for the purification of this enzyme. Each purification step was monitored by testing the column fractions for their ability to complement a mitotic Q2 fraction to ubiquitinate an iodinated amino-terminal fragment of sea urchin cyclin B (residues 13-110) in the presence of ATP and ubiquitin. It has been shown that this amino-terminal fragment of cyclin B is degraded in a cell cycle-dependent way [8] , although this peptide is not able to bind to p34 cdc2 [28] . The column fractions were also analyzed by E2 thioester assays with purified recombinant E1 and radiolabeled ubiquitin. Although the ubiquitination assay was more sensitive, the thioester assay was more linear with respect to the concentration of UBCx.
Our purification scheme is shown in Figure 1a . We prepared fraction Q1 from 220 ml of concentrated Xenopus egg extract (7 g protein). Fraction Q1 was applied to a phenyl sepharose column, from which UBCx eluted at 25 mM ammonium sulfate, much later than UBC4. Active fractions were applied to Hi-Trap Q at pH 9.0. Activity eluted at 150 mM KCl, and the peak fractions were subsequently separated by gel filtration chromatography. Activity eluted with an apparent molecular mass of approximately 30 kDa, as observed previously [16] .
A single ubiquitin thioester of 29 kDa cofractionated with UBCx activity (Fig. 1b,c) , suggesting that the activity was due to a single E2 enzyme with a relative molecular mass of 21 kDa (ubiquitin itself contributes a mass of 8.6 kDa to the thioester). A 21 kDa polypeptide cofractionated with both the ubiquitination and thioester-forming activities (Fig. 1d) , suggesting that this band represented UBCx. This protein was analyzed by amino-acid sequencing of two peptides generated by digestion with Lys-C (Fig. 2) , yielding sequences of 18 residues (peptide A) and 10 residues (peptide B). These peptides did not match any known proteins in the database. However, searches of the expressed sequence tag (EST) database identified three overlapping human ESTs (R80990, R95056, T86566) that encode amino-acid sequences with 83 % identity to peptide A and 80 % identity to peptide B. These three ESTs together encode a predicted protein that is similar in sequence to ubiquitin-conjugating enzymes. Based on the EST sequences, we isolated a cDNA clone (H.s.UBCx-1) from a human testis library that contains an open reading frame of 179 amino acids, corresponding to a 20 kDa protein.
We subsequently cloned the Xenopus UBCx cDNA. Based on the human sequence, we oriented peptides A and B and designed the corresponding degenerate oligonucleotides. These were used as primers in polymerase chain reactions (PCRs) to test pools of a subdivided Xenopus cDNA library [29] for the presence of a Xenopus UBCx clone. Positive pools were then subdivided until single clones were obtained. One clone, designated X.l.UBCx-1, contained a cDNA insert of 1.0 kb and encoded a protein with a predicted mass of 20 kDa (Fig. 2) . A stop codon immediately preceded the initiating methionine, suggesting that this clone contained the complete open reading frame. The sequences of peptides A and B matched the amino-acid sequence encoded by the X.l.UBCx-1 cDNA (Fig. 2) , suggesting that the cDNA encodes the Xenopus UBCx protein.
We expressed the X.l.UBCx-1 cDNA in Escherichia coli and purified the recombinant protein to homogeneity, using a purification protocol similar to that used to purify UBCx from Xenopus extracts (see Materials and methods). The recombinant 21 kDa protein formed a ubiquitin thioester that comigrated on SDS-PAGE with that formed by UBCx from extracts (Fig. 4b) . The recombinant protein could also complement either fraction Q2 or APC immunoprecipitated with CDC27 antibodies (Fig. 4c) . The patterns of cyclin-ubiquitin conjugates formed by the recombinant protein and by UBCx purified from Xenopus egg extracts were indistinguishable. Similar results were obtained with bacterially expressed human UBCx (data not shown). In the presence of mitotic APC, both recombinant proteins were also active in ubiquitinating amino-terminal fragments (residues 1-102) of the Xenopus cyclins B1 and B2 when used as substrates (data not shown). Taken together, these results demonstrate that the isolated cDNAs encode the human and Xenopus versions of the UBCx protein. As the UBCx protein has a molecular mass of 21 kDa but elutes from gel filtration columns with an apparent molecular mass of approximately 30 kDa, it is presently unclear whether the native enzyme is a monomer or a dimer.
Sequence comparison between UBCx and known E2s
showed that UBCx is a novel member of the family of ubiquitin-conjugating enzymes. The highest similarity was observed between UBCx and UBC2 from either yeast or human (approximately 40 % identity at the amino-acid level; Fig. 3 ). However, previous work has shown that recombinant purified human UBC2 is unable to support cyclin ubiquitination [16] , indicating that the two enzymes are functionally distinct.
Based on the sequence homology with other E2s, the cysteine at position 114 of UBCx is likely to be the activesite residue that forms a thioester with ubiquitin. UBCx contains a conserved 16 kDa domain that is characteristic of E2 enzymes [30] ; in this region, UBCx shares relatively low amino-acid identities with the known yeast E2s, ranging from 17-43 %. In addition to the E2 domain, UBCx also contains short amino-and carboxy-terminal extensions. Although Xenopus and human UBCx share 90 % identity in the 16 kDa conserved region, the aminoand carboxy-terminal extensions are only 65 % and 52 % identical, respectively (71 % and 64 % similarities, respectively).
To compare the enzymatic properties of Xenopus UBCx and UBC4, we also isolated a cDNA encoding Xenopus UBC4, which is highly related to the different isoforms of human UBC4 (99 % amino-acid identity to UBC-H5 [24] , 100 % identity to UBC-H5b and 97 % identity to UBC-H5c [31] ). We also expressed Xenopus UBC4 in bacteria and purified the recombinant protein. As shown in Figure 4a , the recombinant proteins used in the subsequent experiments, such as E1, UBC4, and UBCx, were relatively pure. When 
Figure 2
The cDNA and amino-acid sequences of Xenopus UBCx. Two peptides (A and B) that match the amino-acid sequencing data are boxed. The putative active site cysteine (Cys114) is underlined and the stop codon is indicated by an asterisk.
Figure 3
UBCx is a novel member of the E2 family. 
Cyclin ubiquitination mediated by UBCx or UBC4 is D box-dependent
Mitotic cyclins contain a short sequence motif called the destruction box (D box) that serves as the major proteolytic signal. In the case of sea urchin cyclin B, the D box consists of residues 42-RAALGNISN-50 [10] . We tested whether reactions catalyzed by recombinant UBC4 or UBCx were D box-dependent. Four different substrates were used in the reactions: an amino-terminal fragment of sea urchin cyclin B (residues 13-110) [8] , the same fragment with a mutated D box (R42A, A44R, designated AARL) [8] , a shorter cyclin B fragment (residues 13-66) fused to protein A [10] , or a D box deletion mutant of this substrate (⌬DB) (R.W.K. and M.W.K., unpublished results). Ubiquitin conjugates were observed in the presence of the wild-type substrates in both reconstituted systems (Q2 and APC; Fig. 5 ). Point mutation of the D box decreased, but did not eliminate ubiquitination catalyzed by either enzyme, as we had observed previously with UBC4 [16] . In contrast, the ⌬DB substrate yielded no conjugates (Fig. 5 ). These observations suggest that recognition of cyclins by APC requires the intact D box in the reactions reconstituted with either UBC4 or UBCx.
Ubiquitination of the AARL mutant was more strongly suppressed in the presence of fraction Q2 than in those reconstituted with immunopurified APC. This difference could be due to the existence of additional specificity factors in fraction Q2. Alternatively, this may reflect the physical differences of the reaction conditions: the reaction catalyzed by immunopurified APC occurs at the interface between Affiprep beads and components in solution, whereas reactions using fraction Q2 occur entirely in a soluble phase.
UBCx favors the formation of cyclin conjugates with short ubiquitin chains
To compare the activities of Xenopus UBCx and UBC4 in the reconstituted reactions, we analyzed the effect of varying the concentration of the two E2 enzymes in the presence of fixed amounts of fraction Q2 or immunopurified APC. The amounts of conjugates formed in these Research Paper A novel E2 involved in cyclin degradation Yu et al. 459
Figure 4
Recombinant Xenopus UBCx forms a ubiquitin thioester of the same size as the purified protein and catalyzes the formation of cyclinubiquitin conjugates with similar patterns. (a) Recombinant proteins used in subsequent experiments were analyzed by SDS-PAGE (silverstained). Recombinant UBC4 (200 µg ml -1 ) or UBCx (200 µg ml -1 ) was also incubated with E1 (200 µg ml -1 ) and ubiquitin (Ub) (2 mg ml -1 ) in the presence or absence of ATP for 20 min, and 5 µl of each reaction was analyzed by SDS-PAGE and silver-staining. The positions of UBCx-Ub, UBC4-Ub, and E1-Ub thioesters are indicated. (b) E2 thioester assay with either recombinant (50 µg ml -1 ) or purified UBCx. Fraction 15 of the Superdex-75 gel filtration column was used as the source of partially purified UBCx. (c) Ubiquitination assay with either recombinant (50 µg ml -1 ) or purified UBCx in the presence of either a mitotic Q2 fraction or the immunopurified APC (CDC27-IP).
reactions reached plateau levels when 20 µg ml -1 of UBCx or UBC4 was used in the Q2 reaction and 10 µg ml -1 of either enzyme was used in the reactions containing purified APC (Fig. 6 ). At saturation, UBCx converted about 2.5 fold more substrate into ubiquitin conjugates than UBC4 when fraction Q2 was used, and 1.3 fold more when immunopurified APC was used.
We observed a significant difference in the patterns of cyclin-ubiquitin conjugates formed by these two enzymes at all concentrations (Fig. 6) . UBCx favored the formation of low molecular mass conjugates while UBC4 supported the formation of conjugates with higher molecular mass, suggesting that UBC4 is more processive and generates longer ubiquitin chains. For both E2s, the reactions catalyzed by purified APC produced conjugates of lower mass compared to those generated in the Q2 reactions. Presently, we do not know whether this difference results from the physical differences in reaction conditions or is influenced by the presence of additional factors in the Q2 fraction.
When we analyzed cyclin ubiquitination reactions that contained both UBCx and UBC4, we did not see synergy between the two activities. Instead, the amount of substrate converted into ubiquitin conjugates increased additively over a wide range of E2 concentrations (0.5-8 g ml -1 for UBCx; 1-16 g ml -1 for UBC4), either in the presence of fraction Q2 or immunopurified APC (Fig. 7 and data not shown). The profile of the cyclin-ubiquitin conjugates generated in the presence of both UBC4 and UBCx closely resembled the sum of the individual profiles obtained with either UBC4 or UBCx (Fig. 7) .
The cyclin substrate used in our studies, the sea urchin cyclin B fragment (residues 13-110), contains ten lysines that can potentially form isopeptide bonds with ubiquitin. We have found that cyclin amino-terminal fragments are ubiquitinated at multiple sites in crude extracts (R.W.K. and M.W.K., unpublished results). To examine whether the cyclin-ubiquitin conjugates generated by UBCx originate from mono-ubiquitination on multiple sites, we added methylated ubiquitin, a chemically modified molecule that cannot generate polyubiquitin chains, to our reconstituted reactions (Fig. 8) . Four or five major bands were observed for either the UBCx-or UBC4-catalyzed reactions. Because only one molecule of methylated ubiquitin can be attached at each site, the number of bands observed in these experiments corresponds to the number of lysine residues on the substrate that form isopeptide bonds with ubiquitin. Therefore, both UBCx and UBC4 can apparently initiate cyclin ubiquitination at multiple sites. Furthermore, the number of bands did not increase when both UBCx and UBC4 were added in the reaction, suggesting that the two E2s catalyze the attachment of ubiquitin molecules to the same set of lysine residues. In the reactions containing UBCx and immunopurified APC, we observed only a small difference between the patterns of conjugates that were formed in the presence of either ubiquitin or methylated ubiquitin (Fig. 8) . This suggests that UBCx predominantly mono-ubiquitinates cyclin at multiple sites under these conditions.
UBCx and UBC4 catalyze cyclin B ubiquitination with similar kinetics
Cyclin ubiquitination and degradation are rapid processes in vivo and also in mitotic extracts of Xenopus eggs, in which the sea urchin cyclin fragment 13-110 is degraded with a half-life of 5 minutes [16] . Ubiquitin conjugates of this substrate were observed within 1-2 minutes and reached steady state levels within 5 minutes [16] . We obtained similar results when we measured the rate of ubiquitination reactions containing fraction Q2 and either UBCx or UBC4. Conjugates were formed within 1 minute and levels plateaued between 5 and 10 minutes (Fig. 9a) . Identical values were obtained when each E2 was tested at two different concentrations (5 and 20 µg ml -1 for UBCx; 10 and 40 µg ml -1 for UBC4). The reactions containing immunoprecipitated APC were about two fold slower, with plateaus reached at approximately 20 minutes (Fig. 9b) . Compared to UBC4, UBCx converted more substrate into ubiquitin conjugates at a given time. Because the average mass of the UBC4-catalyzed conjugates was higher than that of the UBCx-generated ones, the difference between the two E2s became less dramatic when we plotted the amount of ubiquitin incorporated into cyclin conjugates (data not shown).
UBC4 and UBCx catalyze cyclin ubiquitination with similar kinetics in reactions containing either Q2 or purified APC. We noticed, however, that the amount of conjugates formed by UBC4 in the presence of fraction Q2 decreased after reaching a maximum at 10 minutes (Fig.  9a) . This was mostly due to a decrease in the amount of conjugates containing more than four ubiquitin molecules (Fig. 9d) . In contrast, the total amount of conjugates did not decrease in any of the other reactions. The disappearance of high molecular mass conjugates formed by UBC4 is probably due to degradation catalyzed by 26S proteasomes, which we know are present in fraction Q2 (our unpublished results). Proteasomes preferentially degrade conjugates with long ubiquitin chains [32, 33] , which may explain why the amount of conjugates formed by UBCx was not affected by the presence of fraction Q2. It is also conceivable that fraction Q2 contains deubiquitinating enzymes that preferentially remove longer ubiquitin chains.
Discussion
Exit from mitosis requires the activation of a proteolytic system that degrades cyclin B, the regulatory subunit of the mitotic kinase p34 cdc2 [9, 20] . This destruction system is also thought to initiate anaphase by ubiquitinating and degrading a hypothetical inhibitor of chromosome segregation [7, 8] . We have previously identified several components of this degradation system in mitotic Xenopus egg extracts: a 20S complex that contains a cell cycle-regulated ubiquitin ligase (E3) activity, termed the anaphase-promoting complex (APC), and two ubiquitin-conjugating (E2) enzymes, one of which was identified as a homolog of UBC4 [16] . To complete our identification of the components required for cyclin ubiquitination, we have now purified the second E2 activity, called UBCx, from Xenopus eggs, isolated the corresponding human and Xenopus cDNA clones, and characterized its enzymatic properties.
UBCx is a novel E2 enzyme involved in cyclin ubiquitination
Based on our sequence analysis, UBCx appears to be a novel member of the family of ubiquitin-conjugating enzymes. UBCx is a 21 kDa protein that contains the highly conserved 16 kDa 'E2 domain' found in all members of this family [30] and short amino-and carboxyterminal extensions. Comparison of the human and Xenopus UBCx sequences shows that these extensions are less conserved than the central E2 domain, suggesting that the extensions may not be essential for the enzymatic activity of UBCx.
Several other E2 enzymes have previously been reported to play a role in mitotic cyclin ubiquitination. In budding yeast, UBC9 has been implicated in destruction of Clb2 and Clb5 [27] . A Xenopus homolog of UBC9 has been identified but this enzyme did not cofractionate with the cyclin ubiquitinating activities found in mitotic egg extracts [16] . Our sequence analysis has now confirmed that UBC9 and UBCx are distinct enzymes. Recently, E2-C, an enzyme that can support mitotic cyclin ubiquitination in clam extracts, has been cloned [34] . E2-C shares 65 % amino-acid sequence identity with Xenopus UBCx. This suggests that this E2 is present in a broad range of 462 Current Biology 1996, Vol 6 No 4
Figure 8
UBCx and UBC4 catalyze cyclin ubiquitination at the same set of lysine residues. As indicated, assays were performed with the addition of ubiquitin (Ub) or methylated ubiquitin (MeUb). As indicated, these reactions also contained UBC4 (50 µg ml -1 ), UBCx (20 µg ml -1 ), or both E2s (25 µg ml -1 of UBC4 and 10 µg ml -1 of UBCx) in the presence of CDC27-IP.
metazoan organisms from clam to human. A cDNA identical to human UBCx, termed human E2-C, has also been isolated by Ruderman and coworkers (F. Townsley and J. Ruderman, personal communication). To our knowledge, nine other human ubiquitin-conjugating enzymes have been cloned to date ( [35, 36] ; S. Jentsch, personal communication). We decided in agreement with Ruderman and colleagues to refer to the human homolog of UBCx and E2-C as UBC-H10.
In Xenopus extracts, cyclin ubiquitination can be catalyzed independently by UBCx or UBC4 [16] . In budding yeast, synthetic lethality has been observed between UBC4 and CDC23, a putative subunit of APC, suggesting that these proteins function in the same pathway [15] . Yeast cells from which the genes encoding UBC4 and its close relative UBC5 have been deleted grow extremely slowly but do not show a specific cellcycle arrest [26] . This may be due to the pleiotropic effects of the mutation or to functional redundancy among E2s involved in cyclin ubiquitination. It will therefore be interesting to identify orthologs of UBCx in yeast and to analyze their potential function in cyclin degradation.
UBCx and UBC4 differ in their ability to promote polyubiquitination of cyclin B
In ubiquitination reactions reconstituted with recombinant E2 enzymes, we observed that UBCx converts the cyclin substrate only into low molecular mass ubiquitin conjugates, whereas UBC4 catalyzes the formation of higher mass conjugates, suggesting that UBC4 is more processive. The cyclin-ubiquitin conjugates formed by UBC4 may be more prone to degradation by 26S proteasomes or to disassembly by isopeptidases than those produced by UBCx. This is consistent with the previous observation that 26S proteasomes preferentially degrade conjugates with long ubiquitin chains [32, 33] . Although UBCx appears to be less processive than UBC4, UBCx is active at lower concentrations and converts a greater proportion of the substrate into ubiquitin conjugates.
It is presently unclear why multiple E2s are involved in the ubiquitination of cyclin B. One intriguing possibility is that UBCx and UBC4 play distinct roles in the cyclin ubiquitination reaction. Based on our observations, it is conceivable that the primary function of UBCx may be to initiate ubiquitination by attaching one or two ubiquitin monomers per lysine residue of the substrate. UBC4 could then elongate these short ubiquitin chains to produce conjugates that could be more efficiently recognized by the 26S proteasome. However, we did not observe synergy between UBC4 and UBCx over a wide concentration range in our reconstituted reactions, but this does not rule out the possibility that both E2s cooperate in assembling the polyubiquitin chains on cyclin B under physiological conditions. It is difficult to assess the individual contributions of UBCx and UBC4 under such conditions, as the patterns of the cyclin-ubiquitin conjugates observed in crude extracts are complicated by competing isopeptidase and degradation reactions. Another possibility is that the physiological role of UBCx is to modify the substrate by attaching preformed ubiquitin chains that may exist in vivo [37] . It is also possible that UBC4 and UBCx may be somewhat redundant for cyclin B degradation, but could have more independent functions in the degradation of other substrates that are ubiquitinated by APC at anaphase.
What is the mechanism of cyclin ubiquitination?
Cyclin ubiquitination reactions reconstituted with either UBCx or UBC4 exhibited similar kinetics and were equally APC-and D box-dependent, suggesting that recognition of the cyclin substrate occurs through the same mechanism in both cases. The MAT␣2 degradation system in yeast also involves multiple E2s [23] . In this system, four different ubiquitin-conjugating enzymes promote the degradation of MAT␣2 through two different ubiquitination pathways that recognize distinct degradation signals.
It is presently unclear whether UBCx and UBC4 interact with cyclin directly or whether substrate recognition is exclusively mediated by APC. The latter possibility is more likely for several reasons: UBC4 is known to participate in the ubiquitination of many different substrates [23] [24] [25] [26] and is therefore unlikely to confer substrate specificity directly. In other ubiquitination reactions, such as the N-end rule pathway and p53 ubiquitination, it has also been demonstrated that substrate recognition is mediated by the E3 component, not by the E2 enzyme [38, 39] . In the case of p53 ubiquitination, it has been shown that ubiquitin is transferred through a thioester cascade from E1 via E2 to the E3 (E6-E6AP) [25, 40] . Ubiquitin is then transferred from the E3 to the substrate in an E2-independent reaction. Whether APC, UBCx and UBC4 ubiquitinate cyclin B according to a similar mechanism is still unknown.
The distinct properties of UBCx and UBC4 in the ubiquitination of the same substrate suggest two possible mechanisms and means for distinguishing them. If the mechanism were similar to p53 ubiquitination, UBCx and UBC4 would transfer ubiquitin to APC to form an APC-ubiquitin thioester, which would then donate ubiquitin to cyclin (Fig. 10a) . In one view, where the cyclin would dissociate from APC between each cycle of ubiquitination, we would not expect there to be a difference in the pattern of conjugates, because the nature of the E2s would not influence the subsequent reaction. However, if the cyclin remains bound as shown in Figure 10a , and the ubiquitin transfer from UBCx or UBC4 to APC is rate limiting, then the nature of the E2 could influence the processivity of the reaction. It is also conceivable that UBCx and UBC4 could transfer ubiquitin to different sites on APC. Alternatively, the E2s could transfer ubiquitin directly to the substrate without the formation of a 464 Current Biology 1996, Vol 6 No 4
Figure 10
Hypothetical mechanisms of cyclin ubiquitination. In model (a), ubiquitin is transferred to cyclin via an E1-E2-E3 thioester cascade. Because UBCx and UBC4 catalyze the formation of cyclin-ubiquitin conjugates with distinct patterns, this model can only be valid if k3 is not rate limiting. In this case, UBC4 would transfer ubiquitin to APC with a higher rate than UBCx, allowing more cycles of ubiquitin conjugation during the residence time of the substrate on APC (k1 < k2). In model (b), ubiquitin is transferred directly from E2s to cyclin in a reaction mediated by APC. In this case, no APC-ubiquitin thioester intermediates would be formed and APC would act as an 'adaptor' to bring E2s and cyclin to close proximity. The difference in the pattern of conjugates generated by UBCx and UBC4 could therefore be the result of different rates with which the E2s transfer ubiquitin to cyclin (k1 < k2).
ubiquitin thioester on APC, but in a reaction mediated by APC (Fig. 10b ). In this model, the difference in the processivity of cyclin ubiquitination catalyzed by UBCx and UBC4 would reflect the different rates of ubiquitin transfer to cyclin. UBC4 would transfer ubiquitin to cyclin with a higher rate than UBCx, resulting in the assembly of longer ubiquitin chains during the residence time of cyclin bound to APC. Characterization of the subunits of APC that are involved in E2 binding, substrate recognition, and ubiquitin transfer will help resolve the mechanism of cyclin ubiquitination.
Conclusions
We have purified and cloned UBCx, a novel ubiquitinconjugating enzyme involved in cyclin B ubiquitination in Xenopus. In the presence of mitotic APC, UBCx and UBC4 catalyze the rapid attachment of ubiquitin to cyclin. Both ubiquitin-conjugating enzymes function through similar mechanisms, requiring the anaphase-promoting complex and the same recognition signal on cyclin. However, UBCx and UBC4 generate cyclin-ubiquitin conjugates with different patterns, suggesting that they may play distinct roles in cyclin ubiquitination.
Materials and methods
Protein purification and microsequencing
Interphase and mitotic Xenopus egg extracts and the corresponding high speed supernatants were prepared as described previously [16] . All column chromatography was performed with an FPLC system (Pharmacia) at 4°C. For the purification of UBCx, each column fraction was desalted with PD10 columns (Pharmacia), concentrated in Centriprep-10 concentrators (Amicon), and tested for cyclin ubiquitination and ubiquitin thioester-forming activities. Diluted S100 supernatant was applied to a 50 ml Resource Q column (Pharmacia) equilibrated with buffer Q-A (20 mM Tris-HCl pH 7.7, 100 mM KCl, 1 mM CaCl .2 , 1 mM MgCl .2 , 1 mM DTT). The flowthrough (fraction Q1) was precipitated with 80 % ammonium sulfate. The precipitate was resuspended in buffer P-A (20 mM Tris-HCl pH 7.7, 1.2 M ammonium sulfate, 1 mM DTT), loaded on a phenyl-sepharose column (Pharmacia), and eluted with buffer P-B (20 mM Tris-HCl pH 7.7, 1 mM DTT). The active fractions were exchanged into buffer Q-A9 (20 mM Tris-HCl pH 9.0, 1 mM DTT), applied to a 5 ml Hi-Trap Q column (Pharmacia), and eluted with buffer Q-B9 (Q-A9 + 1 M KCl) with a 0-35 % gradient. The active fractions were then separated on a 125 ml Superdex-75 column (Pharmacia) equilibrated with Q-A. UBCx-containing fractions were separated on 15 % SDS-polyacrylamide gels, transferred to a PVDF membrane (BioRad), and stained with 0.1 % amidoblack in 10 % methanol and 2 % acetic acid. The putative 21 kDa UBCx band was excised (about 2 µg of protein), and processed for peptide sequencing at the Harvard Microchemistry Facility. Briefly, the protein was digested with Lys-C, fragments were separated by HPLC, and two peptides were sequenced by automated Edman degradation. The final preparation of UBCx used for sequencing was derived from a total of 220 ml of concentrated extract.
Cloning of human UBCx and Xenopus UBCx and UBC4
We searched the EST database at the NCBI with the sequence of peptide A using the BLAST network service and found an open reading frame encoded by three ESTs (R80990, R95056, T86566) that matched the query peptide with 83 % identity. On the basis of these EST sequences, we isolated a cDNA from a human testis library using the GeneTrapper cloning system (GibcoBRL). A capture oligonucleotide (5′-AAGACCTGAGGTATAAGCTCTCGC-3′) was synthesized and 5′-biotinylated. A phagemid human testis cDNA library (GibcoBRL) was converted to single-stranded (ss) DNA using Gene II (phage F1 endonuclease) and E. coli Exonuclease III (ExoIII). The biotinylated capture oligonucleotide was then annealed to the ssDNA library and the hybridized DNA was isolated using streptavidin-coated paramagnetic beads. The isolated ssDNA molecules were converted into double-stranded (ds) DNA with the repair enzyme and a repair primer (5′-CACAGTGAAGTTCCTCACGCC-CTG-3′). The dsDNA clones were transformed into E. coli strain DH10B (GibcoBRL) and plated. Colony PCR was used to identify the desired clones. About 10 % of the clones obtained from this procedure were positive. One clone (H.s.UBCx-1) was sequenced on both strands.
For the cloning of Xenopus UBCx, two degenerate oligonucleotides (5′-GGXACXGTXTAYGARGA-3′, 5′-GGRTGRAARCAXGGXGT-3′; X = A/C/G/T; R = A/G; Y = C/T) were designed on the basis of the two peptide sequences. They were used as PCR primers to assay 80 pools of a plasmid library containing cDNA inserts from Xenopus embryos (stage 10-10.5) [28] . Each pool contained about 700 independent clones. The two positive pools were subsequently divided until a single clone was obtained, and one of these, X.l.UBCx-1, was sequenced on both strands.
The Xenopus UBC4 cDNA was isolated in a similar manner, using degenerate oligonucleotides specific for UBC4. The upstream primer was based on the sequence EYPSKPPKV and the downstream primer based on the sequence PNPNSPA. The primer sequence were as follows (I indicates inosine; R = A/G; S = G/C; W = A/T; Y = C/T): Upstream primer: 5′-CCCTCTAGAGGATCCGAITAYCCITCIAARCCI-CCIAARGT-3′; downstream primer: 5′-GGGAAGCTTGAATTCYT-GIGCIGGISWRTTIGGRTTIGG-3′.
Preparation of recombinant ubiquitin-conjugating enzymes
The Xenopus UBCx cDNA was amplified by PCR with Pfu polymerase (Stratagene), digested with NdeI and BamHI (NEB) and subcloned into the pET11c vector (Novagen). The pET-UBCx plasmids were then transformed into BL21(DE3) (Novagen) cells for protein expression. The bacterial lysate was applied to a Hi-Trap Q column equilibrated with Q-A. The flowthrough was precipitated with 80 % ammonium sulfate. The precipitate was resuspended in buffer P-A and loaded on a phenyl sepharose column. The UBCx fractions were concentrated and fractionated with a Sephacryl S100 gel filtration column (Pharmacia). The resulting UBCx protein was greater than 95 % pure, as judged by silver-staining. The human UBCx gene was subcloned into the pET11c vector and the recombinant protein was purified in a similar fashion. The Xenopus UBC4 gene was also subcloned into pET11c and expressed in BL21(DE3) cells. The resulting recombinant UBC4 protein was purified to greater than 80 % purity by cation exchange chromatography using a Hi-Trap SP column (Pharmacia).
Thioester and ubiquitination assays
E2-thioester assays and ubiquitination assays were performed as described [16] . Methylated ubiquitin was prepared as previously described [41] .
